

INNOVATION: THE DRIVING FORCE BEHIND OUR GROWTH

Company Presentation

PHARMANUTRA



"After more than twenty years in business, we can proudly say that the values on which we founded Pharmanutra remain steadfast and still guide every decision we make today: research, innovation, responsibility, and respect for people and their health.

These words have a concrete meaning for us. They form the foundation on which we have built a Group that is now recognised as one of Italy's leading companies in the healthcare sector, with commitment, determination and a touch of healthy ambition.

Our mission is clear: to promote well-being, prevention and health through science. We believe in the power of research and in the ability of innovation to generate value – for our stakeholders, for our employees, and for the society in which we live.

At this stage in our development, we are looking to the future with an even greater sense of responsibility. We are committed to actively contributing to a more sustainable and equitable development model that considers its environmental and social impact.

The Group's headquarters is just one sign of our commitment. Designed to promote collaboration, well-being and circularity, it is a space where we plan the future of health every day.

We are aware of the significant challenges that lie ahead. However, our enthusiasm has never wavered. We will continue to grow with vision, passion, and scientific rigour, carrying forward the virtuous business model that has characterised the first twenty years of our history".

ANDREA AND ROBERTO LACORTE
Founders of Pharmanutra

CONTENTS

ABOUT US	8
RESEARCH AND DEVELOPMENT	18
BUSINESS MODEL	30
SUSTAINABILITY	46
WELFARE	51
SCIENTIFIC DISSEMINATION	52
SPORT	54

Our company in figures

HEADQUARTERS
Pisa Italy

5 Group Companies

1 PHARMANUTRA SPA
2 PHARMANUTRA USA
3 PHARMANUTRA ESPAÑA
4 AKERN
5 ATHLETICA CETILAR PERFORMANCE CENTER

GLOBAL PRESENCE
81 Countries served

STOCK MARKET LISTING
2020
EURONEXT STAR MILAN

144
EMPLOYEES

41 AVERAGE AGE **54%** WOMEN **46%** MEN

60
PRODUCTS ITALIAN MARKET

23
PROPRIETARY RAW MATERIALS

28
REGISTERED PATENTS

204
CLINICAL STUDIES AND PUBLICATIONS

59
REGISTERED TRADEMARKS

Data updated as of 30/06/2026

PHARMANUTRA group

ABOUT US

One Group, one vision: innovating global health

For over 20 years, we have been bringing science into everyday life by developing cutting-edge solutions to promote people's well-being.

The Pharmanutra Group is an Italian company specialising in pharmaceuticals, nutraceuticals and sports products, with a presence in over 80 countries worldwide. We are an ecosystem of companies and expertise that combines scientific vision, industrial strength and entrepreneurial spirit.

Founded in Pisa in 2003, the company is now recognised as one of the finest examples of Italian excellence in the healthcare sector thanks to its development model, which integrates scientific research, proprietary technologies and direct control of the production chain.

Innovation lies at the core of the Group. Through unique patents and cutting-edge clinical studies, Pharmanutra develops effective and safe solutions that enhance quality of life, from early childhood to adulthood.

Adopting an ethical and sustainable approach, the Group promotes responsible growth that respects people, communities and the environment. Pharmanutra's passion for science and commitment to improving global health make it a leading authority for healthcare professionals, patients and consumers.

An integrated ecosystem dedicated to health

Research, innovation, diagnostics and sport: the companies of the Pharmanutra Group share a common vision and diverse, complementary skills.

The Group currently comprises Pharmanutra S.p.A., Akern S.r.l., Athletica Cetilar S.r.l. and two foreign subsidiaries: Pharmanutra U.S.A. Corp. and Pharmanutra España.
Each of the five companies plays a key role in developing advanced health and well-being solutions, from scientific research and production to diagnostics and sports medicine. Together, they strengthen the Group's identity and international leadership.

Pharmanutra S.p.A.

Founded in 2003 by brothers Andrea and Roberto Lacorte, Pharmanutra S.p.A. is the parent company and strategic and operational centre of the entire organisation.
Through its vertical control of the supply chain, from scientific research to production and distribution, Pharmanutra has developed a distinctive model centred on patented technologies and proprietary raw materials, including Sucrosomial® Technology and Cetylated Fatty Acids (CFA).
The Company's leading brands, including SiderAL®, Cetilar® and Apportal®, are now recognised for their effectiveness, quality and innovation in over 80 countries worldwide.
pharmanutragroup.com **pharmanutra.it**

Pharmanutra U.S.A. Corp.

Pharmanutra U.S.A. Corp., the Group's first foreign subsidiary, was established in 2022.
Based in the United States, the company was founded to strengthen Pharmanutra's presence in one of the world's most strategic and competitive markets.
The activities focus on enhancing and promoting the Sucrosomial® Iron patent and trademark, raising awareness of its innovation and strengthening its recognition among healthcare professionals and the general public through e-commerce channels and direct distribution.. Streamlined and dynamic, this model is perfectly in line with the needs of the North American market.
pharmanutra-us.com

Pharmanutra España S.l.u.

Pharmanutra España, established in 2023, is the Group's subsidiary dedicated to development in the Iberian Peninsula.
With an experienced local team and a targeted commercial strategy, the company promotes products from the Cetilar® and Cetilar® Nutrition brands, aiming to quickly become a point of reference for consumers, doctors, pharmacists, and distributors in Spain and neighbouring countries.
The project's defining feature is its combination of local roots and an international vision.

Akern S.r.l.

Akern, a leading company in body composition analysis and bioimpedance measurement, has been part of the Group since 2022.
Akern supports doctors, nutritionists and researchers every day with its high-precision medical instruments and software, helping them to assess health and prevent chronic degenerative diseases.
Akern's scientific expertise is a valuable asset for the Group, enhancing research and development activities in clinical, nutritional and sports fields.
akern.com

Athletica Cetilar S.r.l.

Founded in 2024, Athletica Cetilar is a joint venture between Pharmanutra and Athletica S.n.c., with the latter holding a 30% stake.
Its state-of-the-art facilities are dedicated to sports medicine, physiotherapy, rehabilitation and athletic training, and are designed to meet the needs of professional athletes and others. Its advanced technologies, multidisciplinary expertise and focus on mental and physical well-being define a new, integrated approach to performance.
Athletica Cetilar embodies the Group's dynamic, ambitious and innovative spirit.athleticacetilar.com
athleticacetilar.com



Our History

Two decades of growth, innovation and global vision

For over 20 years, we have been bringing science into everyday life by developing cutting-edge solutions to promote people's well-being.



› 2000

The first company of the future Group, Alesco S.r.l., is founded. It specialises in the research and development of nutraceutical raw materials.

› 2003

Establishment of Pharmanutra S.p.A.
Andrea and Roberto Lacorte combined their scientific expertise and entrepreneurial vision to create a company dedicated to innovation in the nutraceutical and medical fields.

› 2005

Launch of SiderAL®, the Group's first proprietary brand dedicated to iron deficiency.

› 2010

Establishment of Junia Pharma S.r.l.,
with a focus on paediatric products, including food supplements, medical devices and OTC products.

› 2013

Pharmanutra's international expansion of its brands and patents begins.

› 2014

Pharmanutra enters the Italian Stock Exchange's Elite programme for companies with high growth potential

› 2016

Listing on Borsa Italiana's AIM market (now Euronext Growth Milan)

NutraIngredients Award: Sucrosomial® Iron is awarded "Readers' Ingredient of the Year"

› 2019

SiderAL® Forte becomes the best-selling nutritional supplement in Italy. (Federsalus - IQVA data)

› 2020

Transition to the Euronext STAR Milan market, a segment dedicated to SMEs of excellence.

› 2022

Acquisition of Akern S.r.l.
Establishment of Pharmanutra U.S.A. Corp.

› 2023

Inauguration of the new headquarters and research centre in Pisa.
Establishment of Pharmanutra España.

› 2024

Merger by incorporation of **Alesco S.r.l. and Junia Pharma S.r.l.** into Pharmanutra S.p.A.
Establishment of Athletica Cetilar S.r.l.

› 2025

EcoVadis Silver Medal,
top 15%, October 2025

› 2026

Inclusion in the Euronext Tech Leaders Index
Development and launch of the **first communication campaign** dedicated to the new brand, **Sucrosomial Tech®**

Our vision of the future is shaped every day

Science, people and quality: these are the values that guide the Pharmanutra Group towards a new approach to health.

The Pharmanutra spirit is an energetic attitude reflected in all areas and by all professionals. This philosophy inspires all of the Group's choices and projects, promoting sustainable and forward-looking growth.

Vision

The medicine of the future starts before treatment is required.
Our goal is to become a global leader in nutraceuticals and pharmaceuticals by offering advanced solutions that improve quality of life.
We aim to anticipate health needs and respond innovatively to a constantly changing world.

Mission

Proprietary technologies, scientific rigour and a passion for innovation.
Pharmanutra develops products of exceptional added value, resulting from advanced research, direct control of the supply chain, and international distribution.
We provide safe, effective and accessible solutions designed to support well-being and physical performance at every stage of life.



Group values

Our values have always been based on three fundamental principles: science, people and excellence.

Research & Technology

Science is the beating heart of the Group. Every product is born from clinical evidence, patented technologies and a pioneering, methodical approach to research aimed at delivering innovative, effective and unique solutions that make a real difference to people’s daily lives.


People & Health

We put people at the centre: patients, professionals, employees and partners. We act with respect, transparency and responsibility towards society and the environment, aiming to contribute significantly to advancing medicine and improving global health.

Quality & Efficacy

We strive for excellence at every stage, from the selection of raw materials to the production of the finished product. To us, quality means real effectiveness, certified safety and tangible results. Driven by passion and purpose, the Pharmanutra team constantly pushes boundaries, setting ever-higher benchmarks for quality and innovation.

PHARMANUTRA



*Executive board members

PHARMANUTRA group

RESEARCH AND DEVELOPMENT

Innovation and scientific research: our lifeblood

Patents, proprietary raw materials and clinical studies: science is the foundation on which we build every product.

Scientific research is the beating heart of Pharmanutra. Every day, we transform knowledge and intuition into concrete solutions for people's health and well-being.

Thanks to our consolidated expertise and rigorous approach to innovation, we develop unique, safe and highly effective products supported by clinical evidence and proprietary technologies.
Our ongoing commitment to research has resulted in numerous patent filings and trademark registrations, establishing Pharmanutra as a recognised benchmark in the international nutraceutical and medical landscape.

23
PROPRIETARY RAW MATERIALS

28
PATENTS FILED

59
REGISTERED TRADEMARKS

204
CLINICAL STUDIES AND BASIC RESEARCH

Research focus

Nutritional deficiencies
Improving the absorption and bioavailability of essential micronutrients thanks to Sucrosomial® Technology.

Joint and muscle well-being
Developing innovative solutions for physical recovery and mobility, starting with Cetylated Fatty Acids (CFA).

Functional and sports nutrition
Advanced formulations to meet specific needs related to sport, age and clinical conditions.

Body composition analysis
Thanks to Akern, the Group has become a leader in bioimpedance analysis, offering precise technology for health monitoring.

Future Vision

At Pharmanutra, **innovation** is never an end in itself. It is an **ongoing process** aimed at **anticipating the needs of modern medicine** and providing **increasingly effective solutions** for **global well-being**.



Our approach to innovation

Pharmanutra's strength stems not only from a solid and forward-looking scientific vision, but also from concrete and structured investments in innovation.

In the heart of its headquarters in Pisa lies one of Europe's most advanced private biomolecular research centres – a facility designed to promote applied research and accelerate the transfer of technology from laboratory to product.

Our research is never an end in itself – it's a strategic driving force that allows us **to predict clinical requirements, develop distinctive solutions and actively promote progress in global medicine**.

Drawing on an international scientific network

Pharmanutra's R&D activity is based on extensive and well-established collaborations with Italian and international **universities, hospitals, research institutes, and clinical partners**.
These synergies enable us to conduct independent clinical studies, scientific validations and innovative applications, all of which have contributed to the Group's international scientific reputation.



Guaranteed quality, certified safety

Every Pharmanutra product is the result of a controlled process that complies with the most rigorous international standards at every stage.

The Pharmanutra Group adopts a **structured and transparent quality control system**, designed to ensure excellence at every stage of the supply chain: from the selection of raw materials to the distribution of the finished product.

Company certifications

ISO 9001: This certification attests to the company's ability to consistently and effectively provide products and services.

SA 8000: This certification demonstrates the company's commitment to corporate social responsibility, protecting workers' rights and upholding ethical business practices.

ISO 13485: International standard for quality management systems (QMS) specifically designed for the medical device industry.

GMP (Good Manufacturing Practices): This certification relates to the production, packaging, labelling and storage of its patented preparations.

AEO (Authorized Economic Operator): Voluntary European certification attesting to a company's high level of reliability and security within the international supply chain.

Product certifications

The Group holds product certifications attesting to compliance with specific quality, safety and accessibility requirements:

- **Halal and Kosher certifications** for in-house manufactured semi-finished products
- **CE marking** (Class IIa) for medical devices, issued by the Italian National Institute of Health (ISS)
- **Play Sure Doping Free certification**, awarded by Doping Free S.A. and the No Doping Life association following checks by Bureau Veritas Italia S.p.A.


To us, quality is more than just a technical parameter — it's a commitment to health, transparency, and trust. It is a value that sets us apart today and will continue to guide our decisions in the future.

TECHNOLOGIES

Sucrosomial® Technology: a revolution in micronutrient absorption.

A unique, patented delivery system that guarantees the maximum effectiveness in transporting and absorbing essential bioactive compounds.

Sucrosomiale® Technology is an advanced delivery system that protects essential micronutrients and optimises their absorption in the intestine, significantly improving tolerability and clinical efficacy.



At its core is Sucrosoma®, a phospholipid and sucresters structure that encapsulates the active ingredient, transporting it safely and selectively to the intestine for absorption without interference from the gastric environment.

Clinical advantages

- Better absorption
- High gastrointestinal tolerability
- Greater efficacy in less time
- Patented technology supported by scientific evidence

Areas of application

Sucrosomial® Technology was initially developed to address iron deficiency. Since then, it has been extended to include other essential micronutrients such as **magnesium, zinc, selenium, iodine, calcium, chromium, vitamins D3 and B12, plus creatine.**.

In all areas of application, this **innovative patented technology** has proven decisive in not only **correcting** mild and severe **nutritional deficiencies**, but also in effectively preventing further complications and **improving the quality of life** of patients in various clinical fields, including cardiology, gastroenterology, gynaecology, paediatrics, oncology and nephrology.

International recognition

In 2025, the **World Health Organization (WHO)** officially recognised Sucrosomial Technology as an innovation in iron therapy, **incorporating it into its Patient Blood Management (PBM) guidelines**. *

Sucrosomial iron is currently the only oral food supplement recommended for treating iron deficiency anaemia in patients with cardiovascular disease and diabetes.


*WHO, 2025, "Guidance on implementing patient blood management to improve global blood health status".

TECHNOLOGIES

Cetylated Fatty Acids (CFA): a new approach to joint and muscle mobility

This unique technology is based on a patented functional principle and is an effective ally for musculoskeletal health.

CFAs (Cetylated Fatty Acids) are a patented lipid formulation developed by Pharmanutra which supports joint and muscle function through an innovative mechanism.
Consisting of a unique blend of vegetable fatty acids and cetyl alcohol, CFAs stabilise and lubricate cell membranes, thereby improving mobility and reducing inflammation.
Unlike conventional treatments, this technology addresses the root cause of the problem rather than merely managing the symptoms, thereby contributing to the physiological restoration of joint function.



Membrana Cellulare

Advantages of CFAs
- High percentage of cutaneous and systemic absorption
- Rapid and localised action
- Proven effectiveness in sports and medical fields
- Non-pharmacological solution that is well tolerated

Topical formulations – Cetilar® r.m.
In products for external use, such as **Cetilar®**, CFAs reach a concentration of up to 7.5%, ensuring a rapid and targeted effect on the muscle and joint area.
The particular molecular structure allows CFAs to effectively overcome the skin barrier, reaching deep tissues without the need for aggressive chemical vehicles.

Oral formulations – Lipocet®
In 2022, Pharmanutra obtained a patent for **Lipocet®**, a blend of cetylated fatty acids in oral form classified as a **Novel Food**.
This development opens up new therapeutic prospects, providing an effective and safe solution for the daily treatment of musculoskeletal disorders with an approach that **improves functionality rather than just reducing pain**.

Clinical applications
CFAs are currently used in:
- Post-traumatic rehabilitation
- Sports physiotherapy
- Chronic and degenerative joint pain
- Muscle support for professional athletes and active individuals

This patented technology is a prime example of Pharmanutra's approach: methodical innovation focused on improving quality of life.



TECHNOLOGIES

Bioimpedance analysis: understanding the body, guiding health

We use advanced technologies to evaluate, monitor and guide therapeutic choices based on objective data.

Akern is the company within the Pharmanutra Group that specialises in designing and producing medical devices and software for analysing body composition.
Acquired in 2022, it has become the European benchmark in bioimpedance analysis (BIA), a non-invasive technology which quickly and accurately assesses health status by measuring the body's bioelectrical parameters.

Why body composition matters
Measuring weight alone is no longer sufficient. Modern medicine now requires tools that can assess lean mass, fat mass, hydration, cellular status, and other parameters fundamental to the clinical and nutritional management of patients.

BIA enables professionals to:
- identify early imbalances
- monitor the evolution of chronic degenerative diseases
- customise therapies and nutritional plans
- prevent conditions of clinical frailty

Akern technology
Akern instruments stand out for:
- Clinically validated accuracy
- Integrated software enabling advanced medical interpretation
- Intuitive interfaces and instant reporting
- Versatile applications across clinical, sports, and nutritional fields

Thanks to Akern's expertise, the Pharmanutra Group integrates advanced diagnostic tools into its scientific ecosystem, providing a more comprehensive approach to health.

PHARMANUTRA group

BUSINESS MODEL

From science to market

We transform innovation into real value with our integrated, flexible and results-oriented model.

Innovation, manufacturing excellence and intellectual property protection.
These are the cornerstones of the Pharmanutra Group reflected in its integrated and flexible business model driven by market performance, scientific expertise, financial strength, and a competitive time-to-market.

Our goal is not only to innovate, but also to transform that innovation into real value.
We combine science, technology and commercial expertise to provide **a streamlined, responsive and competitive business model**. This is what enables us to make a difference.

1. **Research, production, distribution: an integrated system**
   Pharmanutra develops its own patented raw materials in-house, manages the formulation and supervises all stages of production. This vertical integration ensures quality and traceability, as well as speed of execution, reducing the time between the laboratory and the market.
2. **Global presence, local strategy**
   The Group's strategy is multi-channel and multi-level: in foreign markets, we operate through selected partners and direct subsidiaries; in Italy, we operate through a network of specialised representatives; in the B2C channel, we focus on strong brands and e-commerce platforms.
3. **Collaborations that generate innovation**
   We work alongside universities, clinical institutes, sports centres and technology companies. These partnerships enable us to anticipate emerging needs and develop solutions that address real issues.
4. **Ethics and Sustainability**
   Growth also means having a positive impact. This is why we integrate ESG principles into our daily activities, from corporate welfare to the energy efficiency of our plants.

MARKET

We have a solid, widespread network that is constantly evolving

We have a scientific and commercial presence that combines local presence, digitalisation and direct relations with the medical profession.

In Italy, the Pharmanutra Group operates through two exclusive sales networks: one consisting of Medical Sales Representatives (Scientific Representatives) and the other of Sales Agents. Both networks play a pivotal role in fostering daily relationships with doctors, pharmacists, and other healthcare professionals. Our widespread structure guarantees national coverage and continuity in distribution and scientific information.

Our approach is guided by market performance but is also based on...

1. **Expertise and trust**
   Pharmanutra's Medical Sales Representatives and Sales Agents are highly knowledgeable professionals who continuously update their expertise, enabling them to communicate the scientific value of the products and build long-lasting relationships with healthcare professionals at every level. Pharmanutra invests in continuous training, performance monitoring and skills development to transform its network into a strategic, credible and responsive asset.
2. **Integration with digital channels**
   In 2023, the Group launched its own online store for the Cetilar® and Cetilar® Nutrition brands. Then, in 2025, we launched the Amazon project: our own showcase on the platform with a full range of products.
   The aim is to strengthen the synergy between physical and digital distribution by taking an omnichannel approach, which improves both the shopping experience and the effectiveness of product communication.
3. **Time, quality, results**
   Our ability to quickly translate scientific research into innovative, certified products guarantees a competitive time to market. Over the last three years, Pharmanutra has launched 27 new products on the Italian market, demonstrating an active pipeline and robust yet streamlined organisation.

The Italian market remains a key testing ground for strategies, innovations and brand consolidation.

FOREIGN PARTNERS

A global presence guided by science

We distribute our products worldwide through reliable partners who share our scientific vision.

Pharmanutra operates in foreign markets with a flexible business model centred on solid partnerships and excellence.
Since beginning its international expansion in 2013, the Group has built up an extensive network of **53 distributors operating in 81 countries** across Europe, Asia, Africa and Latin America.

Strategic selection of partners
Each distributor partner is chosen on the basis of specific criteria:
- Experience in the pharmaceutical and nutraceutical sector
- Structured presence in the territory
- Ability to promote innovative products with high scientific content
- Shared values and approach with Pharmanutra

The result is a cohesive, responsive and highly specialised international sales network.

A relationship that goes beyond distribution
The Company shares its expertise in **medical detailing**, marketing best practices, business models, and digital tools with its partners.
The focus is not just on exporting a product, but on **building a local ecosystem** that enhances Pharmanutra's offering and amplifies its market impact.



USA, SPAIN, CHINA

Strategic markets

In the USA, Spain and China, we adopt different models to respond to local specificities and maximise the value of our products

United States: direct presence at the heart of innovation

In 2022, we established **Pharmanutra U.S.A. Corp.**, our subsidiary with operational headquarters in the United States.

Our goal was to enter one of the world's most competitive markets directly with a multi-channel strategy combining **e-commerce**, **retail distribution**, and scientific promotion.

The commercial focus is on promoting and enhancing the value of Sucrosomial® Iron-based products.

The streamlined, localised structure enables the Group to independently manage operations, marketing and commercial development, capitalising on the unique characteristics of the North American market.

Spain: a hybrid model combining direct presence and commercial proximity

In 2023, **Pharmanutra España**, the Group's second foreign subsidiary, was founded.

Its mission is to establish a strong and structured presence in the Iberian market and neighbouring countries. The distribution of Cetilar® and Cetilar® Nutrition branded products is managed directly through e-commerce and online stores.

China: cross-border e-commerce, without physical boundaries

The Chinese market presents both challenges and opportunities.

Pharmanutra has adopted a **fully digital approach**, leveraging **cross-border e-commerce** platforms to sell directly to Chinese consumers without the need for a local office.

Since 2022, our products have been available on four of the country's leading e-commerce platforms.

This model allows the Group to adapt rapidly, efficiently, and at scale to one of the most dynamic markets in the global health & wellness sector.

FOREIGN PARTNERS

Products Pharmanutra

PHARMANUTRA

SUCROSOMIAL® MICRONUTRIENTS

SIDERAL® LINE

Nutritional supplements based on Sucrosomial® Iron (Sideral® r.m.) and vitamins, useful for addressing dietary deficiencies or increased requirements for these nutrients. The Sucrosomial® iron in SiderAL® products reduces the side effects commonly associated with other types of iron, ensuring better absorption and effectiveness, as well as high tolerability.



Food supplement with Sucrosomial® Iron, vitamin C and vitamin B12, useful in cases of nutritional deficiency or increased requirements.



High-dose food supplement with Sucrosomial® Iron and Vitamin C, formulated for optimal absorption. Ideal for adults with specific nutritional needs.



Food supplement with Sucrosomial Iron®, vitamins B6, B12, C and folic acid, to support specific nutritional needs.



Food supplement with Sucrosomial® Iron, vitamins and Quatrefolic®, to support women's needs at every stage of life.



Comprehensive food supplement with Sucrosomial® Iron, essential minerals, plant-based DHA, folic acid, and vitamins – specially designed for use during pregnancy and breastfeeding.



Food supplement with Sucrosomial Iron®, vitamins C, B6 and B12. Useful for supporting all stages of growth.



Food supplement in drop form with Sucrosomial® Iron for high absorption and tolerability, specifically formulated to support growth and development.



Food supplement in drop form with a high concentration of Sucrosomial® Iron, recommended in cases of clinically diagnosed iron deficiency.



Food supplement with Sucrosomial® iron, vitamin C and group B vitamins to support energy levels during development.



Food for special medical purposes (FSMP) containing Sucrosomial® minerals and vitamins for treating severe nutritional deficiencies.



Powdered nutritional supplement based on Sucrosomial® Iron. Available exclusively for healthcare facilities.

SIDERAL® PRODUCTS ACCOUNT FOR 68,1% OF TURNOVER

APPORTAL® LINE

Nutritional supplements based on Sucrosomial® minerals, vitamins and amino acids, designed to support the immune system, normal muscle function, bone health and, in general, the health of our body.



Comprehensive food supplement with 19 nutrients to support the immune system, reduce fatigue and promote recovery during convalescence.



Comprehensive food supplement with 19 nutrients, recommended for loss of appetite, low immunity or convalescence during growth or periods of recovery.



Comprehensive food supplement containing 24 nutrients in a single sachet, designed to support energy levels and help protect against oxidative stress in adults over 50.



Advanced nutritional supplement with 22 nutrients to support energy, vitality and performance during periods of intense physical or mental demand.

APPORTAL® LINE PRODUCTS ACCOUNT FOR 9,2% OF TURNOVER.

CETYLATED FATTY ACIDS

CETILAR® LINE

Topical medical devices and food supplements based on Cetylated Fatty Acids (CFA), for the recovery of joint function and movement in osteoarthritic joint conditions. Cetilar® products are recommended for contusions, strains, sprains, contractures and joint trauma in general.



Topical cream with cetylated fatty acids to promote joint mobility and support daily and sporting activities.



Patches containing Cetylated Fatty Acids with localised, prolonged action to promote muscle and joint recovery.



Non-elastic adhesive strip with Cetylated Fatty Acids, useful in cases of muscle and joint pain, trauma or contractures.



Oral food supplement with cetylated fatty acids, in practical orosoluble sticks, useful for the well-being of muscles and joints.



Cream with Cetylated Fatty Acids (CFA), developed for those who experience joint pain related to growth during adolescence, has a soothing effect and promotes daily joint well-being.

CETILAR® LINE PRODUCTS ACCOUNT FOR 8,9% OF TURNOVER

SIDEVIT® LINE

Food supplements containing Sucrosomial® vitamins, intended for the treatment of dietary deficiencies or when higher organic levels of these nutrients are required. Sidevit® D3 and Sidevit® B12 help support the immune system, energy metabolism, bone health and overall health.



Food supplement with Sucrosomial® Vitamin B12 and Quatrefolic®, the active form of folic acid. High bioavailability, useful in cases of deficiency or increased need for B12 and folate.



A food supplement containing inositol, choline, coenzyme Q10 and B vitamins (B1, B2, B3, B5, B6, B12, biotin and folic acid).



The only food supplement with Sucrosomial® Vitamin D3, offering high bioavailability and tolerability. Recommended in cases of deficiency or increased requirements, even in individuals with absorption difficulties.

OTHER SUCROSOMIAL® PRODUCTS



Food supplement based on Sucrosomial® Magnesium, useful in cases of fatigue, stress, cramps or increased magnesium requirements.



Nutritional supplement based on Sucrosomial® Magnesium and Lactium® (hydrolysed milk proteins), designed to promote night-time rest and alleviate symptoms caused by stress and anxiety.

NATURAL BIOACTIVE COMPOUNDS

Nutritional supplements and OTC products developed and marketed by Pharmanutra, designed to compensate for dietary deficiencies or increased organic nutrient requirements, or simply for everyday health and well-being.



Formulated with EPA and DHA to provide a supplemental intake of nutrients for cardiovascular health support.



Cotton disposable wipes with Chamomile, Cornflower, Zantalene, and Vitamin E extracts for daily eye hygiene and care.



Containing Algal Calcium, vitamin K2 and vitamin D3, useful for supporting the physiological functions of bone tissue.



With Vitamin D, Vitamin E, DHA, phospholipids, and beta-palmitic acid to support immune function and skeletal development.



Spray containing myrrh extract and sodium hyaluronate, useful for treating dryness, colds or oropharyngeal disorders.



Ear solution with myrrh extract, recommended for cleaning the ear and in cases of irritation of the ear canal.

SPORTS NUTRITION

CETILAR® NUTRITION LINE

Cetilar® Nutrition is a complete product range dedicated to athlete nutrition and well-being, designed for those seeking innovative, effective and safe solutions to improve athletic performance. Supporting the needs of athletes taking part in intense sports performances, promoting the supply of essential nutrients and ensuring a reliable source of energy before, during and after physical activity: this is the goal of Cetilar® Nutrition brand products.



Carbohydrate powder



Carbohydrate gel



Carbohydrate powder with caffeine



Carbohydrate gel with caffeine



Carbohydrate powder with caffeine



Carbohydrate gel with caffeine



Energy bar



Protein-energy bar



Protein-energy bar



Protein-energy bar



Protein-energy bar



Rehydration stick



Food supplement of amino acids, B vitamins, selenium and chromium, with fructose and sweeteners



Food supplement containing 100% isolated and hydrolysed whey protein



Creatine monohydrate food supplement with sweeteners



Powdered supplement in sachets for athlete recovery



Food supplement based on Sucrosomial Iron®



Food supplement based on cetylated fatty acids (CFAs)



Powdered supplement in sachets for comprehensive support of the body's natural defences



Sleep support tablet for athletes

Pharmanutra raw material

PHARMANUTRA ingredients

PROPRIETARY RAW MATERIALS (ACTIVE INGREDIENTS)

Sucrosomials® minerals, vitamins and phytoextracts. The innovative, patented phospholipid membrane patented by Pharmanutra allows elements to pass through the gastric environment without reacting with mucous membranes or other nutrients, enabling them to be absorbed directly into the bloodstream.

SideMag marine · SideMag · UltraFer · UltraB12

UltraIod · UltraSel · UltraChrome · UltraD3

UltraCal sea · UltraZin · UltraCal · UltraCrea

OTHER TECHNOLOGIES

UltraJoint

Plant-derived glucosamine to support healthy joint cartilage.

UltraSterol

Microencapsulated phytosterols to help protect heart health and maintain cholesterol levels.

UltraMir

Myrrh extracts with systemic anaesthetic and local analgesic effects, as well as antiseptic and antibacterial properties.

Cetilar r.m.

LipoCet

Cetyl ester complex (CFA) developed to replenish joint fluid and support normal flexibility and mobility of joints, muscles, and tendons.

RAW MATERIALS UNDER EXCLUSIVE LICENCE FOR ITALY

Active ingredients and raw materials marketed for the pharmaceutical, nutraceutical and food sectors.

lactium · Aquamin · BIOENERGY RIBOSE

BIMUNO · Chromax chromium picolinate · Polaris





Akern products

AKERN
Science in body composition

Non-invasive diagnostic tools and medical software for monitoring body composition using bioimpedance techniques.

DIAGNOSTIC TOOLS

NUTRI | LAB PRO

BIA101 | BIVA PRO

BIA101 | MED

MEDICAL SOFTWARE

HBO | HOSPITAL BODYGRAM

BODYGRAM DASHBOARD



PHARMANUTRA group

COMMITMENT



Integrated sustainability: a strategic choice, not a symbolic one

A concrete commitment to the environment, people and the creation of shared value.

For Pharmanutra, sustainability is not just a goal to be achieved; it is a way of doing business.

It is an integral part of the business model and a strategic lever that guides every decision, from scientific research and resource management to relations with the local community and governance.
Through its **ESG Strategic Plan** and **Sustainability Report**, the Group transparently documents the concrete actions it has taken to address the environmental, social and economic challenges of our time.

The three dimensions of sustainability

Pharmanutra adopts an integrated approach based on three complementary pillars:

Environmental sustainability
We reduce our environmental impact through efficient production processes, eco-friendly packaging, using energy from renewable sources and promoting the circular economy.

Social sustainability
We promote collective well-being by providing safe and effective products, educational and cultural initiatives, inclusion programmes, and support for local communities.

Economic sustainability
Our approach to responsible growth is founded on financial strength, continuous investment in research, and unwavering commitment to quality and ethics at every stage of the value chain.

ESG Strategic Plan
The ESG Plan sets out measurable objectives and concrete actions in six key areas:

1. **Governance**: moving towards sustainable and transparent success
2. **People**: enhancing safety and promoting an inclusive culture
3. **Environment**: reducing impact and optimising consumption
4. **Innovation**: protecting intellectual property and conducting responsible research
5. **Community**: supporting social, cultural and educational organisations in the local area
6. **Value chain**: involving suppliers in ESG principles

The annual **Sustainability Report** measures progress and strengthens dialogue with stakeholders. Although it is not a formal obligation, it is a tool that promotes continuous improvement, transparency and trust.



Our contribution to the 2030 Agenda

In line with its mission, Pharmanutra has signed up to the **UN 2030 Agenda for Sustainable Development**, actively contributing to the SDGs (Sustainable Development Goals) most relevant to its business:

	3 HEALTH AND WELL-BEING	5 GENDER EQUALITY	6 CLEAN WATER AND HYGIENE	7 CLEAN AND AFFORDABLE ENERGY	8 DECENT WORK AND ECONOMIC GROWTH	9 INDUSTRY, INNOVATION AND INFRASTRUCTURE	10 REDUCING INEQUALITIES	11 SUSTAINABLE CITIES AND COMMUNITIES	12 RESPONSIBLE CONSUMPTION AND PRODUCTION	13 ACTING FOR THE CLIMATE	14 LIFE UNDERWATER	15 LIFE ON EARTH	16 PEACE, JUSTICE AND STRONG INSTITUTIONS
WASTE MANAGEMENT AND RECYCLING	■		■		■			■	■			■	
ENERGY EFFICIENCY	■			■	■				■	■	■	■	■
MANAGEMENT OF WATER RESOURCES			■	■									
CORPORATE WELFARE AND EMPLOYEE CAREER DEVELOPMENT		■			■		■						
HEALTH AND SAFETY IN THE WORKPLACE	■				■								■
DIVERSITY AND EQUAL OPPORTUNITIES		■			■		■						
RESPONSIBLE PROCUREMENT MANAGEMENT					■								
PRODUCT QUALITY AND SAFETY													■
ETHICS, INTEGRITY AND FIGHT AGAINST CORRUPTION													■
SUSTAINABLE VALUE CREATION		■			■	■		■					


Concrete support for people and the local area

Pharmanutra's commitment to sustainable growth is demonstrated through its **ongoing support of social, educational and cultural projects** that benefit local communities and vulnerable groups.
For years, the Group has collaborated with organisations and foundations that promote inclusion, training, health and well-being, thereby improving the quality of life in the local area.

The main initiatives supported include:

- **I Bambini delle Fate**, which supports inclusion projects for families with disabilities
- **Fondazione Alice Benvenuti ETS**, which provides assistance to families with children undergoing cancer treatment at Meyer Hospital in Florence
- **Rosa Pristina Foundation**, supporting social, humanitarian and research initiatives around the world
- **Fondazione Il Talento all'Opera**: scholarships for outstanding students at the Sant'Anna School of Advanced Studies in Pisa
- **Associazione Per Donare la Vita ONLUS**, which raises awareness of and educates people about organ donation through the solidarity run "15.1 Run"
- **Cultural and Literary Activities**: support for local associations and events, including Fondazione Teatro di Pisa, Giugno Pisano, the "Cronisti in Classe" journalism competition, Scrittori in Borgo and the Edufin project.

For us, sustainability is not just a matter of image; it is a daily commitment. It is a guiding principle that enables us to create value today without compromising the future.



COMMITMENT TO WELFARE

Taking care of people is the first step in building value

At Pharmanutra, the well-being, development and security of our employees form an integral part of our corporate culture.

Companies do not grow on their own; they grow with the people who make them a reality every day.

At Pharmanutra, we believe that talent and determination are equally valuable and that a healthy, stimulating and cohesive environment is the driving force behind innovation. This is why we prioritise the well-being of our employees in our corporate strategy, offering advanced welfare policies, welcoming work environments, and clear career progression.

1. Well-being, health and safety
Our offices are located in a green space designed to improve working life, with communal areas, bright rooms and socialising initiatives to promote physical and mental health.
We prioritise safety every day by investing in increasingly advanced prevention, training and protection programmes.

2. Cohesion and organisational culture
Encouraging collaboration and the exchange of skills, as well as fostering a shared corporate identity, are key objectives of our HR approach.
We foster an open, dynamic, and inclusive environment by implementing practical tools that support work-life balance, alongside services and initiatives designed to respect and enhance both personal and family well-being.

3. Training and potential development
Investing in people means giving them the opportunity to grow.
At Pharmanutra, we support professional development by offering cross-functional and specialised training programmes aimed at enhancing skills, leadership and self-awareness.
Every development journey is crafted to unlock potential and foster a positive, empowering environment.



COMMITMENT TO SCIENTIFIC DISSEMINATION

Shared knowledge, collective progress

Promoting scientific culture is a core part of our mission. Because health is built not only through care, but also through information.

At Pharmanutra, we don't just keep science confined to laboratories.

We believe in our responsibility to disseminate information, raise awareness, explain and educate. This is how we establish transparent dialogue with the scientific community, healthcare professionals, and the younger generation.

Since its foundation, the Group has invested in **research and scientific dissemination projects**, engaging physicians, specialists and researchers at major international congresses and raising awareness of key topics such as **iron deficiency** and related conditions. This commitment is supported by ongoing **training courses (ECM/FAD)** for medical professionals, which contribute to their professional development and the dissemination of evidence-based content.

Academic projects and research

The Group supports research projects in collaboration with the University of Brescia, Fondazione Policlinico Universitario Agostino Gemelli, Sapienza University of Rome, the University of Eastern Piedmont and the University of Pisa.

Università di Brescia · Gemelli Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore · Sapienza Università di Roma · UPO Università del Piemonte Orientale · Università di Pisa

University education and educational partnerships

One of the most significant initiatives is the **Master's Degree in Marketing Management** at the University of Pisa, which strengthens the link between the company and the local area by offering students the opportunity to apply their skills to real projects.

Another important initiative for the future is the launch of the Pharmanutra Academy, a project in collaboration with Italian universities aimed at recruiting and training young talent.

Disseminating means sharing knowledge responsibly. And this is how we intend to contribute to increasingly informed, accessible and evidence-based medicine.

New York Blood Center · TLS Tuscany Life Sciences · Fred Hutch Cancer Center · GALILEO Research · Radcliffe Department of Medicine Medical Sciences Division

COMMITMENT TO SPORT

Sport is our playing field for innovation, education, and shared growth.

Much more than a simple passion. Sport is a tangible extension of the values we believe in: health, commitment, and inclusion.

Through our partnerships with athletes, teams and events at all levels, from elite competitions to grassroots initiatives, the Group promotes healthy and conscious lifestyles and raises awareness of the connection between nutrition, supplementation and performance.

Sponsorships, events, and special projects

Pharmanutra supports numerous sporting organisations with its brands, particularly Cetilar®, including:

- Football, cycling, sailing, motorsport and running teams
- National and international events
- Local initiatives with a high social impact

Among the most significant projects are:


- **Cetilar Academy** a programme dedicated to the sporting and personal development of young talents, including Kart Republic drivers and U.S. Arsenal footballers; and
- **Obiettivo3**, a project founded by Alex Zanardi to introduce people with disabilities to Paralympic sports. Since 2019, Pharmanutra has supported athletes by providing supplies and direct assistance at competitions, with the aim of helping them qualify for the Paralympic Games.

The values we live by, inside and outside the company

"**Sport is in our DNA**. Determination and fun, but also education and respect. These are the values that sport teaches us, and which we live by every day in our company."

Andrea and Roberto Lacorte, founders of Pharmanutra S.p.A.

Being present in the world of sport means giving energy back to the community, shaping positive role models, and proving – by putting values into practice – that health is nurtured not only through products, but also through passion.



PHARMANUTRA group

Sports organizations supported through sponsorship



2026/27 Season



rev. 11.26

Pharmanutra SpA
+39 050 7846500
info@pharmanutra.it
pharmanutragroup.com
pharmanutra.it

Via Campodavela, 1| 56122 Pisa - Italy